Abstract: The present invention provides a pharmaceutical composition for prevention or treatment of a stress disease and depression, the pharmaceutical composition be safely useable without toxicity and side effects by using an extract of leaves of Vaccinium bracteatum Thunb., which is natural resource of Korea, so that the reduction of manufacturing and production costs and the import substitution and export effects can be expected through the replacement of a raw material for preparation with a plant inhabiting in nature.

Abstract: The present invention provides a health functional food composition and a pharmaceutical composition for preventing and alleviating depression, both compositions using an extract of Vaccinium bracteatum Thunb. fruits, which are Korean natural resources, so as to be safely usable without toxicity and side effects.

Abstract: The present invention provides a pharmaceutical composition for prevention or treatment of a stress disease and depression, the pharmaceutical composition be safely useable without toxicity and side effects by using an extract of leaves of Vaccinium bracteatum Thunb., which is natural resource of Korea, so that the reduction of manufacturing and production costs and the import substitution and export effects can be expected through the replacement of a raw material for preparation with a plant inhabiting in nature.

Abstract: The present invention provides a health functional food composition and a pharmaceutical composition for preventing and alleviating depression, both compositions using an extract of Vaccinium bracteatum Thunb. fruits, which are Korean natural resources, so as to be safely usable without toxicity and side effects.

Abstract: The present invention relates to a composition for promoting osteoblast or cartilage cell differentiation. More particularly, the present invention relates to a composition, which includes stauntonia hexaphylla leaf extract that may be safely used without toxicity and side effects by using a natural ingredient, for promoting bone (tissue) formation to be used for suppressing and treating bone and cartilage tissue damage. A pharmaceutical composition including the stauntonia hexaphylla leaf extract according to the present invention as an active ingredient may be used as a medicine for periodontitis or osteoporosis to treat or prevent periodontitis or osteoporosis.

Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.

Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.

Abstract: The present invention relates to a composition for promoting osteoblast or cartilage cell differentiation. More particularly, the present invention relates to a composition, which includes stauntonia hexaphylla leaf extract that may be safely used without toxicity and side effects by using a natural ingredient, for promoting bone (tissue) formation to be used for suppressing and treating bone and cartilage tissue damage. A pharmaceutical composition including the stauntonia hexaphylla leaf extract according to the present invention as an active ingredient may be used as a medicine for periodontitis or osteoporosis to treat or prevent periodontitis or osteoporosis.

Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.